DRKS00033411
Recruiting
N/A
PROstate CAncer Real World Evidence Registry: RECURRENT AND METASTATIC PROSTATE CANCER - PROCARE
roTrials GmbH0 sites5,000 target enrollmentJanuary 15, 2024
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- C61
- Sponsor
- roTrials GmbH
- Enrollment
- 5000
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult prostate cancer patients (age \=18 years).
- •Diagnosis at time of study inclusion
- •Cohort 1: biochemical recurrence (BCR) after local curative intended treatment (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof)
- •Cohort 2: non\-metastatic castration\-resistant prostate cancer (nmCRPC) or
- •Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or
- •Cohort 4: metastatic castration\-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line)
- •Patients who will receive a new line of systemic therapy at the time of study entry or up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a new diagnosis of mCRPC (\=first line mCRPC) after either treatment for mHSPC or non\-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, … line).
- •For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging) to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) or local treatment is declined by the patient.
- •Patients, who are able and willing to sign the informed consent form
Exclusion Criteria
- •Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
ational Registry of Prostate Carcinoma for the Assessment and Improvement of Cross-sectoral Quality of CareC61Malignant neoplasm of prostateDRKS00030737d-uo | Deutsche Uro-Onkologen e.V.6,000
Recruiting
N/A
Prostate cancer Research International: Active Surveillance (PRIAS) MRI studyNL-OMON50734Erasmus MC, Universitair Medisch Centrum Rotterdam30
Recruiting
N/A
ational urothelial carcinoma registry for recording and improving the quality of care across sectorsC67C65C66C68Malignant neoplasm of bladderMalignant neoplasm of renal pelvisMalignant neoplasm of ureterMalignant neoplasm of other and unspecified urinary organsDRKS00026204d-uo | Deutsche Uro-Onkologen e.V.6,150
Recruiting
N/A
Detection of clinically significant prostate cancer with MRI-TRUS fusion image-guided biopsy: comparison of the evaluation system (PI-RADS category vs. PI-RADS + US evalutaion)Suspected prostate cancerJPRN-UMIN000050631Tokai University80
Not Yet Recruiting
N/A
PRO-Health – A prostate cancer specific healthy eating and exercise programACTRN12624000874516Deakin University50